Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, Loftis LL, Tarquinio KM, Singh AR, Heidemann SM, Soma VL, Riggs BJ, Fitzgerald JC, Kong M, Doymaz S, Giuliano JS, Keenaghan MA, Hume JR, Hobbs CV, Schuster JE, Clouser KN, Hall MW, Smith LS, Horwitz SM, Schwartz SP, Irby K, Bradford TT, Maddux AB, Babbitt CJ, Rowan CM, McLaughlin GE, Yager PH, Maamari M, Mack EH, Carroll CL, Montgomery VL, Halasa NB, Cvijanovich NZ, Coates BM, Rose CE, Newburger JW, Patel MM, Randolph AG. Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. New England Journal Of Medicine 2021, 385: 23-34. PMID: 34133855, PMCID: PMC8220972, DOI: 10.1056/nejmoa2102605.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesCombined Modality TherapyCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleGlucocorticoidsHospitalizationHumansImmunoglobulins, IntravenousImmunomodulationInfantLogistic ModelsMalePropensity ScorePublic Health SurveillanceShockSystemic Inflammatory Response SyndromeTreatment OutcomeVentricular Dysfunction, LeftYoung AdultConceptsIntravenous immune globulinMultisystem inflammatory syndromeCardiovascular dysfunctionDay 2Immunomodulatory therapyInflammatory syndromePrimary outcomeInitial treatmentLower riskRisk of feverReal-world effectivenessYears of agePropensity-score matchingImmunomodulatory medicationsVasopressor useVentricular dysfunctionAdjunctive therapyComposite outcomeImmune globulinSecondary outcomesAdjunctive treatmentRecurrent feverInverse probability weightingDay 1GlucocorticoidsNeurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome
LaRovere KL, Riggs BJ, Poussaint TY, Young CC, Newhams MM, Maamari M, Walker TC, Singh AR, Dapul H, Hobbs CV, McLaughlin GE, Son MBF, Maddux AB, Clouser KN, Rowan CM, McGuire JK, Fitzgerald JC, Gertz SJ, Shein SL, Munoz AC, Thomas NJ, Irby K, Levy ER, Staat MA, Tenforde MW, Feldstein LR, Halasa NB, Giuliano JS, Hall MW, Kong M, Carroll CL, Schuster JE, Doymaz S, Loftis LL, Tarquinio KM, Babbitt CJ, Nofziger RA, Kleinman LC, Keenaghan MA, Cvijanovich NZ, Spinella PC, Hume JR, Wellnitz K, Mack EH, Michelson KN, Flori HR, Patel MM, Randolph AG, Last Name* F, Gaspers M, Typpo K, Sanders R, Schwarz A, Harvey H, Zinter M, Mourani P, Coates B, Bhoojhawon G, Havlin K, Montgomery V, Sullivan J, Bradford T, Bembea M, Lipton S, Graciano A, Chen S, Kucukak S, Newburger J, Carroll R, Fernandes N, Yager P, Marohn K, Heidemann S, Cullimore M, McCulloh R, Horwitz S, Li S, Walsh R, Ratner A, Soma V, Gillen J, Zackai S, Ackerman K, Cholette J, Harwayne-Gidansky I, Hymes S, Overby P, Schwartz S, Lansell A, Koncicki M, Carcillo J, Fink E, Kimura D, Bowens C, Crandall H, Smith L, Cengiz P. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurology 2021, 78: 536-547. PMID: 33666649, PMCID: PMC7936352, DOI: 10.1001/jamaneurol.2021.0504.Peer-Reviewed Original ResearchConceptsMultisystem inflammatory syndromeNeurologic involvementInflammatory syndromeLife-threatening conditionHospital dischargeTransient symptomsNeurologic conditionsPositive severe acute respiratory syndrome coronavirus 2 test resultCOVID-19Severe acute respiratory syndrome coronavirus 2Life-threatening neurologic conditionAcute respiratory syndrome coronavirus 2Long-term neurodevelopmental outcomesRespiratory syndrome coronavirus 2Fatal neurologic conditionFulminant cerebral edemaLife-threatening involvementNew neurologic deficitsAcute neurologic signsSyndrome coronavirus 2Coronavirus disease 2019Public health registriesFibrinogen equivalent unitsAdult patientsCerebral edema